MET and breast carcinoma: In a small study comprised of 11 patients with breast cancer (including six patients that showed loss of heterozygosity in the region of the MET gene), no mutations in the tyrosine kinase domain of the MET were identified [30], suggesting that this is not a common event in breast cancer.